Emerging pharmacological treatment options for MAFLD

Metabolic dysfunction–associated fatty liver disease (MAFLD) prevalence and incidence is rising globally. It is associated with metabolic comorbidities, obesity, overweight, type 2 diabetes mellitus, and at least two metabolic risk factors, such as hypertension, hypertriglyceridemia, hypercholestero...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojas, Ángela, Lara-Romero, Carmen, Muñoz-Hernández, Rocío, Gato, Sheila, Ampuero, Javier, Romero-Gómez, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
New Insights in MAFLD
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747889/
https://www.ncbi.nlm.nih.gov/pubmed/36533188
http://dx.doi.org/10.1177/20420188221142452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747889/
https://www.ncbi.nlm.nih.gov/pubmed/36533188
http://dx.doi.org/10.1177/20420188221142452

Ejemplares similares